{"prompt": "['Confidential', 'Prof. Dr. Kristian Reich', 'Clinical Study Protocol', 'APLANTUS 069-008', 'Final 3.0, 07. June 2018', 'Medication-related', 'Ultraviolet B (UVB) therapy, topical steroids, topical calcineurin inhibitors, topical', 'Vitamin A or D analog preparations, or anthralin within 14 days of baseline', 'Exceptions: low potency topical corticosteroids (class I and II, according to European', 'classification for potency of topical corticosteroids) will be allowed as therapy for the', \"face, groin, axillae in accordance with the manufacturer's suggested usage dose\", 'Psoralen plus ultraviolet A radiation (PUVA), ciclosporin, acitretin, alitretinoin, alefacept', '(Amevive), anakinra (Kineret), systemic corticosteroids, methotrexate, fumaric acids', 'or any other systemic anti-psoriasis therapy within 28 days of baseline', 'Prior (within the last 2 years) or concomitant use of antipsoriatic biologic therapy with', 'TNF-alpha blocker and / or ustekinumab and / or ixekizumab and / or secukinumab', 'and / or brodalumab and / or guselkumab', 'Concomitant use of strong cytochrome P450 3A4 (CYP3A4) enzyme inductors (e.g.', \"rifampicin, phenobarbital, carbamazepin, phenytoin and St. John's wort)\", 'Use of an investigational drug within 4 weeks prior to baseline or 5 pharmacokinetic /', 'pharmacodynamics half-lives (whichever is longer)', 'Prior treatment with apremilast / Otezla\u00ae', 'Receipt of any live (attenuated) vaccine within 28 days prior to baseline', 'Concomitant use of any other PDE4 inhibitor', 'Patients with are hereditary problems of galactose intolerance, lapp lactase deficiency', 'or glucose-galactose malabsorption', 'For patients with skin biopsy samples taken: patients with clinically relevant', 'coagulation disorders or medication or known hypersensitivity against local', 'anesthetics', 'Page 31 of 75']['Confidential', 'Prof. Dr. Kristian Reich', 'Clinical Study Protocol', 'APLANTUS 069-008', 'Final 3.0, 07. June 2018', '10', 'Study Medication', '10.1', 'Investigational and Control Drugs', 'The investigational product apremilast is manufactured, packaged and supplied by Celgene', 'Europe Ltd. Table 1 gives an overview of the pharmaceutical information. For labelling refer to', 'Section 10.3.', 'Table 1: Pharmaceutical information', 'Formulation', 'Appearance', 'The Otezla 10 mg film-coated tablet is a pink, diamond', 'shaped film-coated tablet with \"APR\" engraved on one side', 'and \"10\" on the opposite side.', 'The Otezla 20 mg film-coated tablet is a brown, diamond', 'shaped film-coated tablet with \"APR\" engraved on one side', 'and \"20\" on the opposite side.', 'The Otezla 30 mg film-coated tablet is a beige, diamond', 'shaped film-coated tablet with \"APR\" engraved on one side', 'and \"30\" on the opposite side.', 'Active ingredient /', 'apremilast 10/20/30 mg', 'concentration', 'Additional ingredients', 'tablet core:', 'microcrystalline cellulose, lactose monohydrate,', 'croscarmellose sodium, magnesium stearate', 'film-coating:', 'polyvinyl alcohol, titanium dioxide (E171), macrogol, talc,', 'iron oxide red (E172)', '20 mg film-coated tablet also contains iron oxide yellow', '(E172), 30 mg film-coated tablet also contains iron oxide', 'yellow (E172) and iron oxide black (E172)', '10.2', 'Route of Administration, Dosage, Dosage Regimen and', 'Treatment Period', 'Apremilast will be taken orally twice daily (except day 1). Patients will receive tablets in a', 'blister/bottles sufficient for one month. To mitigate potential gastrointestinal side effects', '(primarily mild-to-moderate nausea and diarrhea), dose titration will be implemented in this', 'study in accordance with the treatment guideline for Psoriasis and Psoriasis Arthritis given in', 'the SmPC (31). A titration pack will include tablets of 10, 20 and 30 mg for a period of one', 'month. During the first 1 to 5 days, the dosage will be up-titrated (Table 2). From day 6', 'onwards, patients will receive the 30 mg BID dose. Subsequent packs include only tablets of', '30 mg strength.', 'Table 2: Dosing information', 'Day', 'Morning Dose', 'Evening Dose', 'Total Daily Dose', '1', '10 mg (pink)', '-', '10 mg', 'Page 32 of 75']\n\n###\n\n", "completion": "END"}